Newport Beach, Calif., January 9, 2014 – The CureDuchenne Crusaders will run the Tinker Bell Half Marathon on January 19 to benefit CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, a progressive muscle-wasting disease that impacts 1 in 3,500 boys. Since 2007, the CureDuchenne Crusaders have proudly worn their bright green capes as they’ve walked, ran and climbed mountains to raise funds for Duchenne research.
“Boys with Duchenne are usually diagnosed by the age of 5, in a wheelchair by 12 and most don’t survive their mid-20s,” said Debra Miller, founder and CEO of CureDuchenne. “We are on the run of our life to find a cure for the 300,000 boys worldwide with Duchenne. Our team is running the Tinker Bell Half Marathon for the boys who can’t walk or run. those impacted with Duchenne are the true heroes. They live with a devastating disease every day as their muscles get weaker and weaker. Real progress toward a cure is being made but we urgently need your support.”
Click here to donate to the CureDuchenne Crusaders team running the Tinker Bell Half Marathon. Proceeds will help fund promising research to find a cure for Duchenne. For more information, go to www.cureduchenne.org or call 949-872-2552.
CureDuchenne is a national nonprofit organization located in Newport Beach, Calif., dedicated to finding a cure for Duchenne, the most common and most lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys worldwide. CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne through venture philanthropy.
With the help of CureDuchenne’s distinguished international panel of Scientific Advisors, funds raised by CureDuchenne support the most promising research aimed at treating and curing Duchenne. To date, seven CureDuchenne research projects have made their way into human clinical trials – a unique accomplishment as few health-related nonprofits have been as successful in being a catalyst for human clinical trials.